GlassScriptPhysician profile
Michael Fangerow
NPI 1952697740
$1,070.75
in general payments reported to CMS, 2019-2025
19 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $340 · 2024: $287 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $158.57 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $152.14 | 2023-2025 | |
| Exact Sciences Corporation | $146.00 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $75.78 | 2022-2023 | Freestyle Libre 2, Aveir |
| Gilead Sciences, INC. | $75.71 | 2023-2025 | |
| Viiv Healthcare Company | $66.88 | 2023 | Apretude |
| Daiichi Sankyo INC. | $60.89 | 2023-2025 | Injectafer |
| Glaxosmithkline, LLC. | $59.98 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $50.04 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $43.57 | 2024-2025 | |
| Astellas Pharma US INC | $34.79 | 2025 | Veozah |
| Hologic Sales and Service, LLC | $21.95 | 2025 | Aptima |
| Abbvie INC. | $19.98 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.53 | 2022 | |
| Irhythm Technologies, INC. | $18.45 | 2023 | Zio Xt Patch |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.91 | 2022 | |
| Phadia US INC. | $16.94 | 2024 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $16.16 | 2022 | |
| Dexcom, INC. | $15.48 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fangerow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.